신경보호효과 개선을 위한 약(Pridopidine)으로 현재 2임상시험 중에 있으며 헌팅턴병 증상을 늦추는 효과를 보인다고 합니다.
아직은 임상시험 단계인 약이며 추가 임상시험 단계등의 결과나오면 소식전해드리겠습니다.
finds Teva drug could slow Huntington's disease
Pharmaceutical Industries Ltd. <http://www.tevapharm.com/> today
what could be a major breakthrough in the treatment of
Disease (HD) with positive results from its exploratory Phase
PRIDE-HD study. The trial found a statistically significant impact on the
of the progression of Huntington Disease at 52 weeks following
with Pridopidine at certain doses versus placebo. The effect of
was further evident in a sub-population of patients with early
HD, an effect first observed at 26 weeks.
down the progression of this disease has proven to be impossible
now. These findings give us a reason to believe we may be finally
progress in slowing deterioration of disease," said Spyros
Teva's VP Clinical Development, Neurodegenerative Diseases.
was a 52-week, dose-ranging trial of Pridopidine twice daily versus
in the treatment of Huntington disease (HD). The study was directed
measuring improvement in motor function and the effect on HD progression.
unusually high placebo effect, extending beyond that expected from
studies, limited the ability to determine treatment effects on
of HD motor scores. Evidence of symptomatic impact, however, was
in the early stage HD patient sub-population, with improvement in Total
Score (TMS) and dystonia observed at 26 and 52 weeks in this patient
(stage 1 HD) at specific doses.
discovery of Pridopidine's previously unknown mode of action as a potent
of the Sigma 1 Receptor (S1R) resulted in a change in PRIDE-HD study
from a 26-week study focused on symptoms, to a 52-week study focused
exploring pridopidine's potential impact on disease progression, as
by Total Functional Capacity (TFC).
am encouraged by these results, which provide us with clear insights into
approach to be taken in Phase III development", said Michael Hayden,
of Teva Global R&D and Chief Scientific Officer. "My obvious hope
that this will provide the HD community with a medicine capable of
down the progression of this devastating disease."
study results are very important for the HD community and for the
development of pridopidine. Firstly, pridopidine's safety profile
been confirmed and extended. Secondly, we now have a clearer idea of the
to study in Phase 3. Lastly, we have some of the most encouraging
to date about an intervention which may slow the inexorable
decline of HD," said Karl Kieburtz, M.D., M.P.H., Director of the
& Translational Science Institute at the University of Rochester
results seen in this exploratory study will need to be confirmed in a
III program that will be developed in collaboration with relevant
is an investigational, oral small molecule being developed for
treatment of HD that exerts its effect as an agonist of S1R. S1R plays a
role in neuroprotection through increased production of brain-derived
factor (BDNF). Levels of BDNF are decreased in HD and other
disorders including Parkinson's disease, Alzheimer's
Study Group PRIDE HD Study Information:
. No information available yet on
enrolling for the Phase 3 study.
. No facilities in Florida participated in
the Phase II study: